Quintela-Fandino, Miguel http://orcid.org/0000-0003-1648-1964
Holgado, Esther
Manso, Luis
Morales, Serafin
Bermejo, Begoña
Colomer, Ramon
Apala, Juan V.
Blanco, Raquel
Muñoz, Manuel
Caleiras, Eduardo
Iranzo, Vega
Martinez, Mario
Dominguez, Orlando
Hornedo, Javier
Gonzalez-Cortijo, Lucia
Cortes, Javier
Gasol Cudos, Ariadna
Malon, Diego
Lopez-Alonso, Antonio
Moreno-Ortíz, María C.
Mouron, Silvana
Mañes, Santos
Funding for this research was provided by:
Instituto de Salud Carlos III (PI16/00354, PIE15/00068, PI17/01865)
Comunidad de Madrid (B2017/BMD3733, B2017/BMD3733)
Spanish Ministerio de Economía y Competitividad (SAF2017-83732-R)
Article History
Received: 15 June 2020
Accepted: 25 October 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: Ethics approval was obtained from the Madrid Regional Government Ethics Board for Drug Research and the Spanish Agency for Medicine and Health Products (AEMPS).All participants gave informed consent to participate before taking part of the study.
: Not applicable.
: MQF has received research funds from Astra Zeneca. MQF has received a Research Award from Astra Zeneca Foundation (“Jovenes Investigadores – Cancer 2016”).